Ellis named to new Anheuser-Busch Chair at Barnes-Jewish Hospital

Kathryn Holleman

Sept. 3, 2003 – Matthew J. Ellis, MD, PhD, FRCP, head of Medical Oncology at Washington University School of Medicine is the first holder of the new Anheuser-Busch Chair in Medical Oncology at Barnes-Jewish Hospital.

Dr. Ellis is head of the breast cancer program at the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, an international leader in patient care, cancer research, prevention, education and community outreach and a National Cancer Institute-designated Cancer Center.

The Anheuser-Busch Chair in Medical Oncology was established in 2001 by the Board of Trustees of the Anheuser-Busch Foundation.

"Anheuser-Busch is proud to support the Alvin J. Siteman Cancer Center and is pleased that Dr. Matthew Ellis will fill the first Anheuser-Busch Chair in Medical Oncology at Barnes-Jewish Hospital," said Patrick Stokes, president and chief executive officer of Anheuser-Busch Cos., Inc.  "Anheuser-Busch has always supported the communities where our employees live and work, and we can think of no greater common community goal than to support research efforts that could one day lead to a cure for cancer."

"We are honored and grateful to have the generosity of the Anheuser-Busch Foundation which enabled us to establish this important endowment to support the Alvin J. Siteman Cancer Center," said W. Frank Elston, vice president, Barnes-Jewish Hospital Foundation.

Dr. Ellis came to the Siteman Cancer Center Team this year from Duke University Medical Center where he was clinical director of the Duke University Breast Cancer Program.  He was also associate professor of Medicine, department of Medicine, and division of Oncology and Transplantation.  In addition, Dr. Ellis was co-director of the Breast and Ovarian Cancer Program in the Cancer Center Core Grant.

Dr Ellis obtained his degree in Medicine at the University of Cambridge and his PhD at the University of London.  His doctoral research was conducted at the Imperial Cancer Research Fund.  He came to the United Sates in 1991 on a post doctoral research fellowship from the UK Medical Research Council to study breast cancer at the Lombardi Cancer Center in Washington DC, where he subsequently completed a fellowship in Medical Oncology. His research interests focus on the endocrine treatment of breast cancer, signal transduction therapy and the use of genomic and proteomic profiling to develop a biomaker based treatment approach to disease management.

Back to top